Skip to content
value.today

Vascular Perfusion Solutions, Inc.

🇺🇸 San Antonio, Texas, USABiotechnologyFounded 2016
Total raised
$151 M
3 rounds on record
Latest round
$147 M
May 2025
First round on record
Jun 2019
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Vascular Perfusion Solutions, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2025$147 MNo. 3$50 to $250 million

Vascular Perfusion Solutions, Inc.: Raise no. 3, May 2025

Investors in this round

21 investors had bought by the notice of May 30, 2025: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$147 M of $344 M offered; $197 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • C. Thomas Mayes · Executive Officer, Director
  • Kristina Thomas Andrijauskaite · Executive Officer
  • Leon Bunegin · Executive Officer, Director
  • Rafael Veraza · Executive Officer, Director
  • Toni Thomas Haenninen · Executive Officer
  • Celia Thomas Jairala · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes $4,378,939 value of securities converted in the offering.”

Signed by Rafael Veraza, Ceo. Source: SEC Form D, newest notice filed May 30, 2025. Read the notice at the SEC.

equity, optionsSEC
Aug 2020$2 MNo. 2$2 to $10 million

Vascular Perfusion Solutions, Inc.: Raise no. 2, Aug 2020

Investors in this round

6 investors had bought by the notice of Aug 26, 2020: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $3 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Mark Muller · Executive Officer, Director
  • Paul Perry · Executive Officer
  • Tom DeBrooke · Executive Officer, Director
  • Celia Jairala · Director
  • Klaus Weiswurm · Director
  • Leon Bunegin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “A portion of the proceeds will be used to pay compensation to the executive officers named in response to Item 3 above.”

Signed by Tom DeBrooke, Ceo. Source: SEC Form D, newest notice filed Aug 26, 2020. Read the notice at the SEC.

equitySEC
Jun 2019$2 MNo. 1$2 to $10 million

Vascular Perfusion Solutions, Inc.: Raise no. 1, Jun 2019

Investors in this round

1 investor had bought by the notice of Jun 24, 2019: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $8 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Tom DeBrooke · Executive Officer, Director · President and Chief Executive Officer
  • Celia Jairala · Director
  • Klaus Weiswurm · Director
  • Leon Bunegin · Director
  • Mark Muller · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “A portion of the proceeds will be used to pay compensation to the executive officers named in response to Item 3 above.”

Signed by Tom DeBrooke, President. Source: SEC Form D, newest notice filed Jun 24, 2019. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Vascular Perfusion Solutions, Inc. chose not to state its revenue in its newest notice of a funding round (May 2025).

    SEC Form D · May 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · May 2025

That is all the official record says: Vascular Perfusion Solutions, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Vascular Perfusion Solutions, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 21 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Vascular Perfusion Solutions, Inc.
NameRoleNamed in
C. Thomas MayesExecutive officerMay 2025
Kristina Thomas AndrijauskaiteExecutive officerMay 2025
Leon BuneginExecutive officerMay 2025
Rafael VerazaExecutive officerMay 2025
Toni Thomas HaenninenExecutive officerMay 2025
Mark MullerExecutive officerAug 2020
Paul PerryExecutive officerAug 2020
Tom DeBrookeExecutive officerAug 2020
C. Thomas MayesDirectorMay 2025
Celia Thomas JairalaDirectorMay 2025
Leon BuneginDirectorMay 2025
Rafael VerazaDirectorMay 2025
Celia JairalaDirectorAug 2020
Klaus WeiswurmDirectorAug 2020
Mark MullerDirectorAug 2020
Tom DeBrookeDirectorAug 2020